NHS Dudley Health Economy Medicines Formulary
Home > 8 Malignant disease and immunosuppression > 8.1 Cytotoxic drugs > 8.1.5 Other antineoplastic drugs > Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line) - NICE TAG TA189

Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line) - NICE TAG TA189

1.1 Sorafenib is not recommended for the treatment of advanced hepatocellular carcinoma in patients for whom surgical or locoregional therapies have failed or are not suitable.

1.2 People currently receiving sorafenib for the treatment of advanced hepatocellular carcinoma should have the option to continue treatment until they and their clinician consider it appropriate to stop.

https://www.nice.org.uk/guidance/TA189

Site by Devopa
© Copyright 2020 NHS. All rights reserved.